Delivery Order SPE2DB20D1051-SPE2DB25FD9JX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Insulin Aspart 100 Unit/ML pens (3ML) with a ceiling value of $9,672.58. This firm fixed price delivery order, which is not associated with a set-aside program, represents a competitive procurement to support federal medical supply needs. The order is scheduled for completion by August 14, 2025, and will be fulfilled from AmerisourceBergen's corporate office located in...
- The Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a for-profit subsidiary of Amerisourcebergen Corporation, to provide 4,563,557,490 units of insulin aspart 100 unit/mL pens. The $7,975.68 contract has a completion date of February 6, 2024 and was awarded on February 5, 2024. This delivery order contract is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 and a performance...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.42 on August 19, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL). This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procurement with no set-aside designation. The place of...
- The Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The contract, valued at $2,195.52, is for the provision of Insulin Aspart 100 unit/mL pens with a completion date of January 31, 2024. Amerisourcebergen Drug Corp serves as the prime contractor on this delivery order, which is part of a larger indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL) with a ceiling value of $2,262.05. This is a firm fixed-price delivery order with an ultimate completion date of July 24, 2025, and represents a non-competitive set-aside contract. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate...
- The Defense Logistics Agency awarded a $4,196.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10mL) on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,219.80 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Insulin Aspart 100 Unit/ml in 10ml vials. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by September 10, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a...
- The U.S. Department of Defense's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,463.20 for Insulin Aspart 100 Unit/mL vials (10mL) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's existing Indefinite...
- The U.S. Defense Logistics Agency (DLA) has awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract to provide Insulin Aspart 100 Unit/mL Pen 3mL. The contract has a potential value of $28,673.28 and a completion date of January 31, 2024. This delivery order is issued under a single award indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that runs through December 31, 2025. The IDC serves as the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL) under a firm fixed-price contract with a ceiling value of $1,238.72. The contract, which is not set-aside and competitively awarded, is scheduled for completion by August 22, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- SPE2DB20D1051Indefinite Delivery Contract
- SPE2DB20D1051-SPE2DB25FD9JXDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Insulin Aspart 100 Unit/mL pens (3mL) under a firm fixed-price contract with a ceiling value of $1,865.96. This non-set-aside delivery order is scheduled for completion by September 11, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical supplier to federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order is executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. As a major pharmaceutical distributor, AmerisourceBergen has demonstrated capability to meet federal procurement requirements through open competition and maintains a substantial portfolio of medical product deliveries supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 9/10/25 |